Other immunological mechanisms such as activation of CTLs, were not investigated in our study and could also contribute to protection observed in our vaccination protocol. [64]. Moreover, it was already well established that T. gondii infection elicits robust innate and acquired immune response in
the gastrointestinal AZD2014 clinical trial tract [65] and [66]. CD4+ T cells from the lamina propria produce chemokines and cytokines (i.e. IFN-γ, TNF-α, MCP-1, etc.) that helps to clear the parasite. CD8+ T intraepithelial lymphocytes, in addition to their cytolytic activity, secrete TGF-β that help to reduce the inflammation [67] and [68]. Although the role of specific IgA antibodies secreted in lamina propria remains unclear, it plausible that these antibodies also help to protect the host against oral infection [69] and [70]. Thus, a future prospect of our work would be to elucidate if our vaccination protocol is able to elicit specific mucosal anti-SAG2 immune response. In conclusion, our work shows the successful use of Ibrutinib in vivo recombinant influenza and adenoviruses in vaccination protocols to protect against oral challenge with T. gondii. These recombinant viruses encoding T. gondii antigens could be used to generate human and veterinary vaccines against toxoplasmosis. We thanks to Dr George Brownlee, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom who kindly
provided most of plasmids use in reverse genetics experiments; Irla Paula Stoppa for laboratory assistance; Dr inhibitors Sylvie van der Werf, head of Laboratory of RNA Viruses, Institut Pasteur Paris, for intellectual support and the Statitistical Staff of René Rachou Institute for out their help in the statistic analysis. This work was supported by grants from FIOCRUZ/PDTIS-Vacinas, and Millennium Institute for Vaccine Development and Technology (CNPq – 420067/2005-1), CNPq/MAPA/SDA N° 064/2008, National Institute of
Health (NIH; Grant Number NIAID U01 AI 77887) and FAPEMIG. Fellowships were provided by CNPq to AVM, RPAB, RHR, BCC and RTG. “
“Viral interference refers to a phenomenon, whereby infection by one replication-competent virus results in the inhibition of replication of another replication-competent virus. Viral interference has been reported as early as 1954 [1]. A defective interfering virus containing replication origin plays a key role in viral interference. However, viral interference between replication-deficient viruses is still unknown. In this study, we explored antigen-specific immune response induced by co-immunization of the adenovirus (Ad) vector and modified vaccinia virus Ankara (MVA) vector in vivo and transgene expression by two viral vectors in vitro. In the last decade, several novel vaccine platforms have been studied for their utility in the development of prophylactic vaccines against infection by viral pathogens (e.g., HIV, hepatitis, and influenza viruses).